Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome

Advances in Therapy

Volumn 25, Issue 11, 2008, Pages 1105-1140

  Krag, Aleksander ^a   Borup, Tine ^a   Møller, Søren ^a   Bendtsen, Flemming ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Cirrhosis; Hepatorenal syndrome; Portal hypertension; Terlipressin; Variceal bleeding

Indexed keywords

DRUG DERIVATIVE; LYPRESSIN; MIDODRINE; NORADRENALIN; OCTREOTIDE; SOMATOSTATIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT;

ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; PARACENTESIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE, ACUTE; LYPRESSIN; MIDODRINE; NOREPINEPHRINE; OCTREOTIDE; PARACENTESIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOMATOSTATIN; VASOCONSTRICTOR AGENTS;

EID: 77449099990     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0118-7     Document Type: Review

References (155)

1. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7: 122-128. (Pubitemid 17019862)
2. Colle I, Durand F, Pessione F, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol. 2002;17:882-888.
3. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival afer variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652-659. (Pubitemid 39265587)
4. McCormick PA, O'Keefe C. Improving prognosis following a frst variceal haemorrhage over four decades. Gut. 2001;49:682-685. (Pubitemid 32989206)
5. Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. Lancet. 1982;2:66-68. (Pubitemid 12075461)
6. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet. 2003;362:1819-1827. (Pubitemid 37494763)
7. Martín-Llahí M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352-1359. (Pubitemid 351626950)
8. Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830-835. (Pubitemid 351317073)
9. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360-1368. (Pubitemid 351615358)
10. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-231. (Pubitemid 41772537)
11. Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis. 2006;26:348-362. (Pubitemid 44632926)
12. Abraldes JG, Villanueva C, Banares R, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol. 2008;48: 229-236.
13. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481-488. (Pubitemid 47187350)
14. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fbrosis: a meta-analysis. Gastroenterology. 2008;134:960-974.
15. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. (Pubitemid 351323895)
16. Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis. 1999;19:397-410. (Pubitemid 30032641)
17. Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol. 2005;39:S125-S130. (Pubitemid 40397025)
18. D'Amico G, de Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599-612. (Pubitemid 37052147)
19. Te North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the frst variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983-989.
20. Bambha K, Kim WR, Pedersen RA, Bida JP, Kremers WK, Kamath PS. Predictors of rebleeding and mortality following acute variceal hemorrhage in patients with cirrhosis. Gut. 2008;57:814-820. (Pubitemid 351716977)
21. Bendtsen F, Krag A, Møller S. Treatment of acute variceal bleeding. Dig Liver Dis. 2008;40:328-336.
22. de Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis. 1999;19:439-455. (Pubitemid 30032644)
23. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29:1655-1661. (Pubitemid 29247035)
24. D'Amico G, Luca A. TIPS is a cost Effective alternative to surgical shunt as a rescue therapy for prevention of recurrent bleeding from esophageal varices. J Hepatol. 2008;48:387-390.
25. Graham DY, Smith JL. The course of patients afer variceal hemorrhage. Gastroenterology. 1981;80:800-809. (Pubitemid 11137765)
26. Stokkeland K, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. Hepatology. 2006;43:500-505.
27. Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Infuence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis. 1999;19:427-438. (Pubitemid 30032643)
28. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology. 2003;124:1277-1291. (Pubitemid 36531803)
29. Kowalski HJ, Belmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest. 1953;32:1025-1033.
30. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet. 1956;271:1121-1125.
31. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151-1157.
32. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:S121-S131.
33. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646-1654.
34. Schrier RW. Decreased Effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol. 2007;18: 2028-2031. (Pubitemid 47041067)
35. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38(suppl. 1):S69-S89.
36. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38:1210-1218. (Pubitemid 37314829)
37. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439-447. (Pubitemid 41061097)
38. Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med. 1970;49:175-185.
39. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007;46:935-946. (Pubitemid 46529046)
40. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310-1318. (Pubitemid 47300435)
41. Alessandria C, Ottobrelli A, Bernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47:499-505. (Pubitemid 47331744)
42. Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 2002;14:153-158. (Pubitemid 34163994)
43. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923-930. (Pubitemid 34267275)
44. Mulkay JP, Louis H, Donckier V, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg. 2001;64:15-19. (Pubitemid 32291099)
45. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941-948.
46. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103:1689-1697.
47. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Benefcial Effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18:152-156. (Pubitemid 36349860)
48. Testro AG, Wongseelashote S, Angus PW, Gow PJ. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol. 2007;23:1535-1540.
49. Forsling ML, Aziz LA, Miller M, Davies R, Donovan B. Conversion of triglycylvasopressin to lysine-vasopressin in man. J Endocrinol. 1980;85:237-244. (Pubitemid 10123081)
50. Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin afer single i.v. doses to healthy volunteers. Drugs Exp Clin Res. 1990;16:307-314.
51. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1-receptor physiology. Crit Care. 2003;7:427-434. (Pubitemid 37527228)
52. Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology. 2007;46:1863-1871.
53. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun. 1994;203: 72-79. (Pubitemid 24281062)
54. Walker BR, Childs ME, Adams EM. Direct cardiac Effects of vasopressin: role of V1-and V2-vasopressinergic receptors. Am J Physiol. 1988;255:H261-H265.
55. Boyle WA 3rd, Segel LD. Direct cardiac Effects of vasopressin and their reversal by a vascular antagonist. Am J Physiol. 1986;251:H734-H741.
56. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med. 2007;35:33-40. (Pubitemid 46035674)
57. Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology. 2006;105:599-612. (Pubitemid 44310444)
58. Fenton RA, Knepper MA. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol Rev. 2007;87:1083-1112. (Pubitemid 350033821)
59. Nielsen S, Frøkiær J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002;82:205-244. (Pubitemid 34654219)
60. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic Effects of terlipressin in portal hypertensive patients. Liver. 2000;20:51-59. (Pubitemid 30095288)
61. Romero G, Kravetz D, Argonz J, Bildozola M, Suarez A, Terg R. Terlipressin is more Effective in decreasing variceal pressure than portal pressure in cirrhotic patients. J Hepatol. 2000;32:419-425. (Pubitemid 30136856)
62. Kiszka-Kanowitz M, Henriksen JH, Hansen EF, Møller S, Bendtsen F. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol. 2004;39:486-492. (Pubitemid 38626630)
63. Merkel C, Gatta A, Bolognesi M, et al. Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci. 1988;33:1103-1109.
64. Hansen EF, Bendtsen F, Brinch K, Møller S, Henriksen JH, Becker U. Endoscopic Doppler ultrasound for measurement of azygos blood fow. Validation against thermodilution and assessment of pharmacological Effects of terlipressin in portal hypertension. Scand J Gastroenterol. 2001;36:318-325. (Pubitemid 32234584)
65. Baik SK, Jeong PH, Ji SW, et al. Acute hemodynamic Effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol. 2005;100:631-635. (Pubitemid 40487563)
66. Escorsell A, Bandi JC, Moitinho E, et al. Time profle of the haemodynamic Effects of terlipressin in portal hypertension. J Hepatol. 1997;26:621-627. (Pubitemid 27112728)
67. Lin HC, Yang YY, Hou MC, et al. Hemodynamic Effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis. Scand J Gastroenterol. 2002;37:482-487.
68. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the Effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology. 2001;120:161-169. (Pubitemid 32061880)
69. Villanueva C, Planella M, Aracil C, et al. Hemodynamic Effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. Am J Gastroenterol. 2005;100:624-630. (Pubitemid 40487562)
70. Nevens F, Van SW, Yap SH, Fevery J. Assessment of variceal pressure by continuous non-invasive endoscopic registration: a placebo controlled evaluation of the Effect of terlipressin and octreotide. Gut. 1996;38:129-134. (Pubitemid 26020939)
71. Cestari R, Braga M, Missale G, Ravelli P, Burroughs AK. Haemodynamic Effect of triglycyl-lysine-vasopressin (glypressin) on intravascular oesophageal variceal pressure in patients with cirrhosis. A randomized placebo controlled trial. J Hepatol. 1990;10:205-210. (Pubitemid 20089162)
72. Lote CJ, McVicar AJ, Tewles A. Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. J Physiol. 1987;391:407-418. (Pubitemid 17161448)
73. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profle of receptor resensitization. J Biol Chem. 1999;274:32248-32257.
74. Krag A, Bendtsen F, Pedersen EB, Holstein-Rathlou NH, Moller S. Effects of terlipressin on the aquaretic system-evidence of antidiuretic Effects. Am J Physiol Renal Physiol. 2008 Epub ahead of print
75. Nadvornikova H, Schuck O. The infuence of a single dose of vasopressin analogs on human renal potassium excretion. Int J Clin Pharmacol Ter Toxicol. 1982;20:155-158. (Pubitemid 12148830)
76. Stephan F, Paillard F. Terlipressin-exacerbated hypokalaemia. Lancet. 1998;351:1249-1250. (Pubitemid 28181968)
77. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43:167-176. (Pubitemid 40805288)
78. Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ter. 2003;17:53-64. (Pubitemid 36140434)
79. Hu RH, Lee PH. Open, randomized, comparative study of efcacy and safety between Haemopressin and Glypressin in treating acute esophageal varices hemorrhage. Hepatogastroenterology. 2008;55:448-452.
80. Bruha R, Marecek Z, Spicak J, et al. Double-blind randomized, comparative multicenter study of the Effect of terlipressin in the treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding. Hepatogastroenterology. 2002;49:1161-1166. (Pubitemid 34809812)
81. Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet. 1995;346:865-868.
82. Söderlund C, Magnusson I, Torngren S, Lundell L. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol. 1990;25:622-630. (Pubitemid 20186798)
83. Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology. 1986;6:112-115. (Pubitemid 16137853)
84. Pauwels A, Florent C, Desaint B, Van Guivarch PH, Levy VG. Terlipressin and somatostatin in the treatment of hemorrhages from rupture of esophageal varices (letter) French. Gastroenterologie Clinique Biologique. 1994;18:388-389. (Pubitemid 24207269)
85. Brunati X, Ceriani R, Curioni R, Brunelli L, Repaci G, Morini L. Sclerotherapy alone vs scherotherapy plus terlipressin vs sclerotherapy plus octreotide in the treatment of acute variceal hemorrhage. Hepatology. 1996;24:207A.
86. Patch D, Caplin M, Greenslade L, Burroughs A. Randomized double blind controlled trial of 5 day terlipressin vs placebo in acute variceal hemorrhage. J Hepatol. 1999; 30(suppl. 1):55.
87. Garcia-Tsao G, Groszmann RJ. Portal hemodynamics during nitroglycerin administration in cirrhotic patients. Hepatology. 1987;7:805-809. (Pubitemid 17139228)
88. Moitinho E, Planas R, Banares R, et al. Multicenter randomized controlled trial comparing diferent schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol. 2001;35: 712-718. (Pubitemid 34717661)
89. Ottesen LH, Flyvbjerg A, Møller S, Bendtsen F. The organ extraction and splanchnic haemodynamic Effects of octreotide in cirrhotic patients. Aliment Pharmacol Ter. 1998;12:657-665. (Pubitemid 28327963)
90. Møller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol. 1997;26:1026-1033. (Pubitemid 27242592)
91. Gotzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2008;(3):CD000193.
92. Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology. 2002;35:609-615. (Pubitemid 34183965)
93. Fort E, Sautereau D, Silvain C, Ingrand P, Pillegand B, Beauchant M. A randomized trial of terlipressin plus nitroglycerin vs. balloon tamponade in the control of acute variceal hemorrhage. Hepatology. 1990;11:678-681. (Pubitemid 20151748)
94. Garcia-Compean D, Blanc P, Bories JM, et al. Treatment of active gastroesophageal variceal bleeding with terlipressin or hemostatic balloon in patients with cirrhosis. A randomized controlled trial. Arch Med Res. 1997;28:241-245. (Pubitemid 27280898)
95. Colin R, Giuli N, Czernichow P, et al. Prospective comparison of glypressin, tamponade and their association in the treatment of bleeding esophageal varices. In: Lebrec, D, Blei, AT, eds. Vasopressin Analogs and Portal Hypertension. Paris: John Libbey Eurotext; 1987:149-153.
96. Pedretti G, Elia G, Calzetti C, Magnani G, Fiaccadori F. Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin Investig. 1994;72:653-659. (Pubitemid 24304081)
97. Silvain C, Carpentier S, Sautereau D, et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology. 1993;18: 61-65. (Pubitemid 23193618)
98. Walker S, Kreichgauer HP, Bode JC. Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices-fnal report of a placebo-controlled, double-blind study. Gastroenterol. 1996;34:692-698. (Pubitemid 26348010)
99. Feu F, Ruiz del Arbol L, Banares R, Planas R, Bosch J. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology. 1996;111:1291-1299. (Pubitemid 26362254)
100. Escorsell A, Ruiz del Arbol L, Planas R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology. 2000;32:471-476.
101. Wechowski J, Connolly M, Woehl A, et al. An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis. Curr Med Res Opin. 2007;23:1481-1491. (Pubitemid 47122157)
102. Connolly M, Bhatt A, Wechowski J, Colle I. An economic evaluation of vasoactive agents used to treat acute bleeding oesophageal varices in Belgium. Acta Gastroenterol Belg. 2008;71:230-236. (Pubitemid 351976346)
103. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008;48(suppl. 1):S93-S103.
104. Arroyo V, Gines P, Gerbes AL, et al. Defnition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164-176. (Pubitemid 26012105)
105. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002;36:374-380. (Pubitemid 34810356)
106. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004;40:140-146. (Pubitemid 38064723)
107. Barcrof H, Konzett H. On the actions of noradrenaline, adrenaline and isopropyl noradrenaline on the arterial blood pressure, heart rate and muscle blood fow in man. J Physiol. 1949;110:194-204.
108. Swan HJ. Noradrenaline, adrenaline, and the human circulation. BMJ. 1952;1:1003-1006.
109. Bellomo R, Giantomasso DD. Noradrenaline and the kidney: friends or foes? Crit Care. 2001;5:294-298. (Pubitemid 34130322)
110. Pittner H, Turnheim K. Pulmonary and systemic circulatory Effects of midodrine, a new sympathomimetic, and its metabolite, ST 1059. Arch Int Pharmacodyn Ter. 1974;207:180-192.
111. Angeli P, Volpin R, Piovan D, et al. Acute Effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998;28:937-943. (Pubitemid 28450253)
112. Kalambokis G, Economou M, Fotopoulos A, et al. The Effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005;100:879-885.
113. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol. 2007;46:213-221. (Pubitemid 44959158)
114. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690-1697. (Pubitemid 29247040)
115. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55-64. (Pubitemid 38868923)
116. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy signifcantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52:742-748.
117. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 2003;38:238-243. (Pubitemid 36775816)
118. Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, et al. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial. Hepatology. 2001;34:471-477. (Pubitemid 32786636)
119. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be benefcial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant. 2005;20:1813-1820. (Pubitemid 41222593)
120. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493-1502.
121. Moreau R, Asselah T, Condat B, et al. Comparison of the Effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut. 2002;50:90-94. (Pubitemid 34028309)
122. Lata J, Marecek Z, Fejfar T, et al. The efcacy of terlipressin in comparison with albumin in the prevention of circulatory changes afer the paracentesis of tense ascites-a randomized multicentric study. Hepatogastroenterology. 2007;54:1930-1933.
123. Singh V, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008;103: 1399-1405. (Pubitemid 351813906)
124. Eefsen M, Dethlof T, Frederiksen HJ, Hauerberg J, Hansen BA, Larsen FS. Comparison of terlipressin and noradrenalin on cerebral perfusion, intracranial pressure and cerebral extracellular concentrations of lactate and pyruvate in patients with acute liver failure in need of inotropic support. J Hepatol. 2007;47:381-386. (Pubitemid 47189608)
125. Shawcross DL, Davies NA, Mookerjee RP, et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology. 2004;39:471-475. (Pubitemid 38222188)
126. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev. 2003;(1):CD002147.
127. D'Amico G, Traina M, Vizzini G et al. Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis. A randomized clinical trial. Liver Study Group of V. Cervello Hospital. J Hepatol. 1994:20:206-212. (Pubitemid 24086834)
128. Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology. 2008;134:1715-1728. (Pubitemid 351626956)
129. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999;30:870-875. (Pubitemid 29458273)
130. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998;27:35-41. (Pubitemid 28041531)
131. Lee MY, Chu CS, Lee KT, et al. Terlipressin-related acute myocardial infarction: a case report and literature review. Kaohsiung J Med Sci. 2004;20:604-608.
132. Rosario R, Lalanne B, Lebre P, et al. Myocardial infarction afer injection of terlipressin for digestive hemorrhage. Gastroenterol Clin Biol. 1996;20:712-713. (Pubitemid 26323071)
133. Urge J, Sincl F, Prochazka V, Urbanek K. Terlipressin-induced ventricular arrhythmia. Scand J Gastroenterol. 2008;43:1145-1148.
134. Kelly KJ, Stang JM, Mekhjian HS. Vasopressin provocation of ventricular dysrhythmia. Ann Intern Med. 1980;92: 205-206. (Pubitemid 10141581)
135. Eden E, Teirstein A, Wiener I. Ventricular arrhythmia induced by vasopressin: torsade de pointes related to vasopressin-induced bradycardia. Mt Sinai J Med. 1983;50:49-51. (Pubitemid 13123294)
136. Mauro VF, Bingle JF, Ginn SM, Jafri FM. Torsade de pointes in a patient receiving intravenous vasopressin. Crit Care Med. 1988;16:200-201.
137. Kupferschmidt H, Meier CH, Sulzer M, Meier PJ, Buhler H. Clinico-pharmacological case. Bradycardia and ventricular tachycardia of the torsades de pointes type as a side Effect of vasopressin: 3 case reports. Praxis. 1996;85:340-343.
138. Faigel DO, Metz DC, Kochman ML. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance. Am J Gastroenterol. 1995;90:822-824.
139. Stein LB, Dabezies MA, Silverman M, Brozena SC. Fatal torsade de pointes occurring in a patient receiving intravenous vasopressin and nitroglycerin. J Clin Gastroenterol. 1992;15:171-174.
140. Klein GJ. Vasopressin, "torsades de pointes", and QT syndrome. Ann Intern Med. 1980;93:511-512.
141. Ouattara A, Landi M, Le MY, et al. Comparative cardiac Effects of terlipressin, vasopressin, and norepinephrine on an isolated perfused rabbit heart. Anesthesiology. 2005;102:85-92. (Pubitemid 40082844)
142. Wu IC, Yu FJ, Chou JJ, et al. Predictive risk factors for upper gastrointestinal bleeding with simultaneous myocardial injury. Kaohsiung J Med Sci. 2007;23:8-16.
143. Di Micoli A, Bracci E, Cappa FM, et al. Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome. Dig Liver Dis. 2008;40:304-305.
144. Donnellan F, Cullen G, Hegarty JE, McCormick PA. Ischaemic complications of Glypressin in liver disease: a case series. Br J Clin Pharmacol. 2007;64:550-552. (Pubitemid 47404308)
145. Lee JS, Lee HS, Jung SW, et al. A case of peripheral ischemic complication afer terlipressin therapy. Korean J Gastroenterol. 2006;47:454-457.
146. Vaccaro F, Giorgi A, Riggio O, De SA, Laviano A, Rossi-Fanelli F. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-Effects? A case report. Dig Liver Dis. 2003;35:503-506. (Pubitemid 41070445)
147. Oh JE, Ha JS, Cho DH, Yu GJ, Shim SG. A case of ischemic skin necrosis afer glypressin therapy in liver cirrhosis. Korean J Gastroenterol. 2008;51:381-384.
148. Willems MG, Schoenemann J, Rey C, Schafer H, Lindecken KD. Ischemia of the cecum caused by glycylpressin in German. Leber Magen Darm. 1985;15:165-168. (Pubitemid 15007635)
149. Hansen M, Bjerg J, Gilsaa T. Terlipressin and reversible intestinal ischaemiain Danish. Ug e sk r L a e g e r. 2007;169:1802-1803.
150. Schmitt W, Wagner-Tiessen E, Lux G. Ischaemic colitis in a patient treated with glypressin for bleeding oesophageal varices. Hepatogastroenterology. 1987;34:134-136. (Pubitemid 17104483)
151. Machova A. Antidiuretic activity of terlipressin (triglycyl-lysine vasopressin)-role of pressure natriuresis. Physiol Res. 1992;41:121-127.
152. Douriez E, Mollard P, Laval C, Albengres E, Laporte JP, Tillement JP.
153. Dunwoodie E, Jowett S. Terlipressin causing a hyponatraemic seizure. Scand J Gastroenterol. 2007;42:665.
154. Chalasani N, Kahi C, Francois F, et al. Improved patient survival afer acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol. 2003;98:653-659. (Pubitemid 36348540)
155. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41:1282-1289. (Pubitemid 40770280)